FK 506: an immunosuppressant for the 1990s?
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 1702172.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The novel macrolide immunosuppressant FK 506 is a powerful and selective anti-T-cell agent which has a similar mode of action to that of cyclosporin. Clinical studies of FK 506 in liver allograft recipients indicate a lower risk/benefit ratio than with cyclosporin, and wider evaluation of FK 506 in transplant recipients is now under way in multicentre, prospective, controlled trials in both Europe and North America.